Cannabis and Hemp Industry Investment News
The pot pill maker filed applications related to the company’s technologies in oral dosing
Ltd () announced today that it recently filed two additional Canadian patent applications, bolstering its intellectual property portfolio. Canntab's portfolio now includes 13 applications in Canada, the US and internationally.
The company, which offers medical marijuana in pill form, said the new applications were related to oral formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and sustained release cannabinoid pellets. Canntab is the first company to offer medical marijuana in pill form in Canada and possibly the rest of the world.
READ: Canntab Therapeutics unveils major milestone, with Canada Health approval for its sustained release product
The new patent applications extend Canntab’s intellectual property portfolio, which includes patent applications and trademark applications in the United States and Canada.
Canntab is currently developing a number of products, which include an extended-release tablet that contains a mixture of THC (tetrahydrocannabinol) and CBD (cannabidiol) that may be helpful in the treatment of a number of ailments.
Earlier this month, the group inked a letter of intent to acquire up to an 85% interest in the two vanadium permits
Energy metals group () saw its shares rise as it told investors that it has submitted a work programme with Exco Mining SA to explore for vanadium in Spain.
Earlier this month, the group inked a letter of intent to acquire up to an 85% interest in the two vanadium permits in Badajoz in central Spain covering 500 square miles.
Major step forward
The deal included two further permits in southern Spain, covering cobalt, copper, nickel and manganese.
() announced it has appointed pharmaceutical executive Bob Woloschuk to its advisory board.
Bob has more than two decades of executive experience in the pharmaceutical industry and an eye for licensing opportunities, both in Canada and in international markets, the firm said.
READ: Canntab Therapeutics unveils major milestone, with Canada Health approval for its sustained release product
"We are grateful for the opportunity to add someone of Bob's calibre to our advisory board, which already included some of the most impressive names in both capital markets, and cannabis research and development,” said chief executive officer, Jeff Renwick, who is also a director.
Canntab’s advisory board is also made up of researcher Sabrina Ramkellawan, cannabis leader Hamish Sutherland and medical doctor, Dr. Eric Hatashita.
“Bob has a long history of successful business development within the key "Big Pharma" industry players, and has significant experience developing licensing strategies in the pharmaceutical industry,” said Renwick. “We look forward to working with Bob, who we believe adds tremendous value to our advisory board and the company as a whole.”
The trial will test the safety, efficacy and dose tolerance in cancer patients.
Ltd () has commenced the trial of NanaBis™, its cannabis-based medicine for advanced cancer pain at Royal North Shore Hospital (RNSH) in Sydney.
The trial will test the safety, efficacy and dose tolerance in cancer patients with both managed and unmanaged pain.
Medlab managing director Dr Sean Hall said: “This is what we have been working towards.
“It’s a key milestone for the company, we have a validated GMP Australian manufactured product that is being used in a robust and much-needed trial.”
Canntab says it will begin making the first pivotal batch of the product this week
Ltd () has unveiled a major milestone - as the firm along with partner () have received Health Canada approval for research and development activities on oral sustained release formulations of Canntab's cannabinoids product, sending shares higher.
Canntab has brought equipment to Emblem’s Ontario location and will begin making the first pivotal batch of the product this week, using its patented technology and proprietary processes.
READ: Canntab Therapeutics extends its intellectual property portfolio
The pair struck a collaboration and licensing deal in October last year related to development, regulatory approval, manufacturing, and commercialisation of Canntab’s patent-pending sustained release product.
“The extended release tablet is the perfect pharmaceutical dosage form," said Jeffrey Renwick, chief executive at Canntab.
The company recently made three additional US patent applications and one international patent application
Ltd () has now filed 11 patents related to pharmaceutical cannabis.
These filings, which include seven non-provisional United States patent applications and four patent co-operation treaty (PCT) patent applications, build on Canntab's growing intellectual property portfolio.
READ Pot pill maker Canntab Therapeutics debuts on Canadian exchange, shares pop
These patent applications are part of Canntab's concerted strategy to develop a comprehensive intellectual property portfolio that covers the company's technology and formulations related to pharmaceutical preparations that contain natural or synthetic cannabinoids.
Canntab is currently developing a number of products that use this technology, which includes a variety of extended released tablets containing a mixture of THC (tetrahydrocannabinol) and CBD (cannabidiol) that can be used to treat a number of ailments, such as sleep disorders, post-traumatic stress disorder (PTSD), social anxiety, addiction, arthritis, general pain, and the pain management and appetite loss associated with cancer treatments.
The Coachella City Planning Commission has recommended that the city council grant a conditional use permit for High Hampton's CoachellaGro facility, which it is expected to do at its next meeting
High Hampton Holdings Corp () has moved a step closer to building its CoachellaGro cannabis production facility in California after local planning bosses gave their backing to the 10.8-acre site.
On Tuesday, the Coachella City Planning Commission recommended that Coachella City Council grant a conditional use permit for the property.
That’s the last stage in the process and High Hampton expects the permit to be formally issued at the next city council meeting later this month.
“It has been a diligent application process with significant work completed by our executive management team and our experienced infrastructure engineers team, and we are very pleased to have received an approval from the Coachella Planning Commission to award a conditional use permit,” said Chief Executive David Argudo.
The Green Organic Dutchman completed an initial public offering of 31.5mln units at a price of $3.65 per unit.
In one of the most-anticipated cannabis initial public offerings of the year, () commenced trading on the Toronto Stock Exchange today. The IPO of 31,510,000 units at price of C$3.65 per unit, could see total gross proceeds of C$115,011,500.
The research and development company is licensed under Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. TGOD says it has an aim to be one of the largest organic cannabis companies in the world, with a position as one of Canada’s lowest-cost producers.
Company has close ties to
The company raised over C$160mln in funding before the IPO. Much of the anticipation behind the IPO was as a result of the company’s close ties with Inc (), where an earlier strategic investment was completed in January 2018.
Today, participated in the IPO of The Green Organic Dutchman, purchasing 17.5% of the initial public offering issue (6.3 million units), for a total investment of C$23.1mln.
The OTCMarkets were down across the board Wednesday afternoon.
Shares of Corp (OTCQX:IGAMF) sunk 22% in afternoon trading after disappointing fourth-quarter results. The Vancouver-based company owns and operates 2,700 slot machines in Oklahoma and Texas casinos. Revenue increased 1% to US$4.1mln compared to US$4.0mln in the same quarter last year. The company changed CEOs earlier this month and changed its name to Integrity Gaming Corp at the beginning of 2018.
Galaxy Gaming Inc (OTCQB:GLXZ) shares jumped more than 17% after announcing a complete debt refinancing. The company develops, manufactures, and distributes casino table games. The credit agreements allows for US$12mln in borrowing capacity, with US$11mln via a five-year loan and US$1mln in a one-year revolving credit facility. The company also announced a stock buyback of up to US$1mln worth of shares.
Biotech company Bioscience Corp (OTCQX:LXRP) shares are up more than 3% after announcing a licensing agreement with California cannabis beverage maker GP Holdings LLC. The Vancouver-based company is providing its patented DehydraTECH technology that allows for high absorption of cannabis.
, Inc (OTCQB:KAYS) has opened its fourth legal marijuana dispensary in Oregon. Located in a strip mall alongside fast food chains like Popeye’s and Carl’s Jr., the stores sell a variety of cannabis and cannabis-infused products like blood orange white chocolate bars and body care products like pain relief topical oils. The stores also offer home delivery of the products within Salem, Oregon. Shares were up 5.7% in afternoon trading.
The company's Australian JV partner recently entered into a binding MoU with Burleigh Heads Cannabis, which holds an import licence issued by the Australian Office of Drug Control
Ltd () has engaged a consultant to advise on its application for a dealer licence in Canada.
Trevor Moore, a veteran of the Canadian medical cannabis industry, has been retained by the company to assist in preparing its application to obtain a Health Canada dealer licence under the Controlled Drugs and Substances Act (CDSA) and its associated regulations.
READ Pot pill maker Canntab Therapeutics debuts on Canadian exchange, shares pop
Moore has previously helped two licensed producers obtain their licences and is an expert in the areas of quality assurance, regulatory compliance and government relations.
Securing a dealer's licence will allow Canntab to continue with the development of its proprietary products, including the extended-release tablet (XR tablet), and will allow Canntab to manufacture and sell the products in Canada and elsewhere.
A collaborative distribution agreement would see the two parties selling both their products into the Australian market.
Auscann Group Holdings Limited (), a leading medical cannabis company, has received an import permit under its existing import licence.
Following this development, the company will soon receive finished cannabis oils from its major shareholder, Canopy Growth Corporation.
AusCann and Canopy Growth are pursuing opportunities in several key areas in Australia including the importation, distribution and local production of medical cannabis products.
AusCann managing director Elaine Darby said: “Our ongoing relationship with Canopy Growth offers major benefits for AusCann and we are very pleased to be working with Canopy Growth as the Australian market expands.
Jeff Renwick, CEO of (CSE: PILL) tells Proactive Investors that the company that produces oral marijuana tablets is going public on the same day it was incorporated two years ago, and a day that pot enthusiasts celebrate as "Weed Day."
Renwick says as part of the strategic initiative to go public, the company plans to roll out a product development line and will next execute its distribution plan.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Ltd () shares started trading on the Canadian Securities Exchange on Friday, offering traders another way to play the cannabis industry on the most significant day of the year for marijuana enthusiasts.
The company offers medical marijuana in pill form — the first to do so in Canada, and possibly the rest of the world — the reason being that a pot pill would be easier to digest and better for the health of those who have trouble smoking.
Shares popped past C$1 in early trading.
The company is headed by CEO Jeff Renwick with Chief Financial Officer Richard Goldstein. Barry M. Polisuk, Sheldon Inwentash and Vitor Fonseca are directors.
A significant day to debut
The once-private group was founded April 20, 2016, by pharmaceutical industry professionals and comes to the public market after merging with shell resource group Telferscot Resources.
Friday Night Inc shares shot up over 11% on the news...
Cannabis- focused Friday Night Inc (CSE:TGIF, OTCQB:TGIFF) saw shares shoot up 11% Thursday on the back of an announcement about its new acquisition Spire Secure Logistics and Canada.
In late February, the group said it had acquired Spire, which specializes in security and has expertise in the cannabis industry. It closed the deal in March.
Spire is led by experts with international backgrounds in covert and undercover operations to infiltrate and disrupt organized crime, including cartels and other violent gangs.
The new subsidiary is to provide strategic advice and expertise to a Canadian provincial government on security programs and infrastructure for the legal distribution and sale of cannabis, Friday Night said.
High Hampton Holdings Corp. (OTCMKTS:HHPHF, CSNX:HC) is looking to develop its private cannabis distribution network through the state of California.
The Toronto-based company is looking specifically at the Coachella Valley, home to the popular namesake music festival.
“We’re looking at existing brands and existing companies that are in the California landscape. The beachhead for us is a property in Coachella,” said COO Paul Mann.
The company acquired 10.2 acres of land in the valley, which includes 190 square feet of greenhouses and 90,000 square feet of production space where the manufacturing, production, and packaging will take place.
The cannabis investment company raised US$19.3mln in a March offering.
Friday Night’s priority is building a new 67,000 sq ft building to boost production...
Nevada-focused Friday Night Inc (CSE:TGIF, OTCQB:TGIFF) represents a 'compelling' investment opportunity in the legal cannabis space, according to an article on CFN Media.
"In addition to its existing revenue growth, the company’s Nevada facility is nearing final approval and could produce significant shareholder value over the coming years once complete," it says.
READ THE ARTICLE HERE..
Friday Night’s priority is building a new 67,000 sq ft building to boost production.
After acquiring the land and securing zoning approval, it is now awaiting final plan approval from the county.
Subsidiary Infused Mfg has struck the agreement with Grizzly Griptape, which was founded by skateboard legend Torey Pudwill
Nevada-focused cannabis group (CSE:TGIF, OTCQB:TGIFF) has skated into the action sports market with a new one-year licensing agreement.
Subsidiary Infused Mfg has struck the deal with skateboard firm Grizzly Griptape, founded by skateboard legend Torey Pudwill, for Infused's newest product - 'Canna Hemp X', which includes a CBD-infused recovery cream targeting the rapidly growing sports recovery market.
READ - Friday Night nudges higher as sales increase 20% in second quarter
"We are excited to launch our new action sports Recovery Cream in collaboration with Grizzly Griptape", Brayden Sutton, president and chief executive of Friday Night, told investors.
"Torey Pudwill is a legendary name in skateboarding and it has been a pleasure to work with him and the team at Grizzly.
Alternative Medicine Association (AMA) has increased its focus on producing higher quality plants. Sales were up 11%
Shares in recreational cannabis group (CSE:TGIF, OTCQB:TGIFF) nudged higher as it reported a 20.2% increase in total sales in the second quarter against the first.
The figure for the latest quarter came in at over C$2.96mln compared to C$2.46mln in the first quarter.
The increase was contributed to by both subsidiaries in Las Vegas, Nevada, the firm said.
Alternative Medicine Association (AMA) has increased its focus on producing higher quality plants that command a higher price in the marketplace. Sales were up 11%.
Special access scheme will accelerate the plan to supply medicinal cannabis products.
() has achieved a major breakthrough following the establishment of a special access scheme which enables access for Chilean patients to medicinal cannabis products.
AusCann’s joint venture partner, Fundación Daya has worked with the Chilean National Institute of Public Health to establish the special access scheme.
READ: AusCann Group's vertically integrated model provides point of difference in medicinal cannabis industry
A similar access scheme is used in Australia, which enables doctors to prescribe cannabinoid medicines prior to product registration.
Second cannabis crop is getting ready for harvest
AusCann and Fundación Daya’s joint venture, DayaCann, is the only company in Chile to hold a medical cannabis production licence.
Control of the supply chain offers operational advantages and financial benefits.
AusCann Group Holding Ltd () has adopted a strategy that should see it ideally positioned to take advantage of burgeoning global demand for medicinal cannabis.
While there has been an influx of ASX-listed companies targeting this market, there are few that are developing a vertically integrated model, as is the case with AusCann.
Supply chain control offers definite operational advantages, and traditionally, brings financial benefits to any research, manufacturing, production and distribution business.
By developing a fully integrated pharmaceutical cannabinoid company, taking charge of all aspects from cultivation through to manufacturing and distribution, Auscann has distinct advantages over many of its peers.
